Impact of treatment-emergent ocular events on health-related quality of life in patients with folate receptor alpha-positive platinum-resistant ovarian cancer treated with mirvetuximab soravtansine: Results from the phase III MIRASOL study

IF 4.1 2区医学 Q1 OBSTETRICS & GYNECOLOGY

Gynecologic oncology Pub Date : 2025-09-01 DOI:10.1016/j.ygyno.2025.03.102

Tashanna Myers , Kathleen Moore , Laurence Gladieff , Yolanda García-García , Gottfried Konecny , Rosalind Glasspool , Domenica Lorusso , John Moroney , Vincent Renard , Marta Mongillo , Andrea Jewell , Dagmara Klasa-Mazurkiewicz , Jacqueline Tromp , Mario Beiner , Melissa Hardesty , Anna Kryzhanivska , Purificación Estévez-García , Aolin Wang , Erin Zagadailov , Jerome Alexandre , Toon Van Gorp

引用次数: 0

查看原文本刊更多论文

mirvetuximab soravtansine治疗的叶酸受体α阳性铂耐药卵巢癌患者治疗后出现的眼部事件对健康相关生活质量的影响：来自MIRASOL III期研究的结果

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Gynecologic oncology 医学-妇产科学

CiteScore

8.60

自引率

6.40%

发文量

1062

审稿时长

37 days

期刊介绍： Gynecologic Oncology, an international journal, is devoted to the publication of clinical and investigative articles that concern tumors of the female reproductive tract. Investigations relating to the etiology, diagnosis, and treatment of female cancers, as well as research from any of the disciplines related to this field of interest, are published. Research Areas Include: • Cell and molecular biology • Chemotherapy • Cytology • Endocrinology • Epidemiology • Genetics • Gynecologic surgery • Immunology • Pathology • Radiotherapy